BYOMass Inc.
The startup develops preclinical pharmaceutical therapeutics that target specific members of the transforming growth factor (TGF-) superfamily to treat orphan and common diseases. Its novel biological and small molecule drugs aim to provide effective treatment options for oncology, inflammatory, immune, fibrotic, and metabolic diseases with high unmet medical needs.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$6.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops preclinical pharmaceutical therapeutics that target specific members of the transforming growth factor (TGF-) superfamily to treat orphan and common diseases. Its novel biological and small molecule drugs aim to provide effective treatment options for oncology, inflammatory, immune, fibrotic, and metabolic diseases with high unmet medical needs.